Table 3.
Treatment over time among NSTEMI patients, in all patients, by country, (%).
| Admission year | 2007 | 2008 | 2009 | 2010 | 2007–2010 | ||
|---|---|---|---|---|---|---|---|
| In-hospital angiography | MINAP (UK) | 22.9 | 27.9 | 35.5 | 38.8 | 31.8 | |
| RIKS-HIA (Sweden) | 60.4 | 62.7 | 66.8 | 69.8 | 64.8 | ||
| ACTION (US) | 72.4 | 75.2 | 76.6 | 78.3 | 76.0 | ||
| In-hospital PCI | MINAP (UK) | 16.5 | 20.0 | 23.4 | 26.1 | 21.8 | |
| RIKS-HIA (Sweden) | 39.0 | 40.2 | 42.7 | 45.9 | 41.9 | ||
| ACTION (US) | 41.8 | 43.3 | 44.2 | 45.5 | 43.9 | ||
| Betablocker at discharge | MINAP (UK) | 73.1 | 74.9 | 76.5 | 78.7 | 76.0 | |
| RIKS-HIA (Sweden) | 88.8 | 88.6 | 88.2 | 89.0 | 88.6 | ||
| ACTION (US) | 90.1 | 89.4 | 89.1 | 89.1 | 89.4 | ||
| Antiplatelet at discharge | Any | MINAP (UK) | 94.2 | 94.0 | 94.7 | 95.4 | 94.6 |
| RIKS-HIA (Sweden) | 93.6 | 94.4 | 95.0 | 94.9 | 94.5 | ||
| ACTION (US) | 95.0 | 95.1 | 95.6 | 95.7 | 95.4 | ||
| Dual | MINAP (UK) | 74.9 | 74.6 | 76.4 | 78.6 | 76.2 | |
| RIKS-HIA (Sweden) | 63.2 | 66.9 | 70.6 | 72.4 | 68.1 | ||
| ACTION (US) | 64.7 | 65.1 | 66.9 | 68.0 | 66.4 | ||
| Statin at discharge | MINAP (UK) | 91.2 | 91.0 | 91.5 | 92.1 | 91.5 | |
| RIKS-HIA (Sweden) | 79.7 | 81.4 | 82.7 | 83.6 | 81.1 | ||
| ACTION (US) | 82.0 | 83.7 | 85.4 | 85.9 | 84.5 | ||
| ACEI or ARB at discharge | MINAP (UK) | 77.1 | 77.5 | 79 | 80.6 | 78.7 | |
| RIKS-HIA (Sweden) | 65.5 | 68.3 | 69.9 | 72.1 | 68.8 | ||
| ACTION (US) | 65.9 | 64.5 | 64.3 | 63.9 | 64.5 | ||
N = 137,009 for MINAP (UK), 45,069 for RIKS-HIA (Sweden), and 147,438 for ACTION (US).
Abbreviations same as in Tables 1 and 2.